Wells Fargo & Company Humanigen, Inc Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$0.13 - $0.2 $4 - $6	31 Added 0.83%	3,780 $0
Q1 2023 May 12, 2023	BUY	$0.12 - $0.23 $12 - $24	107 Added 2.94%	3,749 $0
Q4 2022 Feb 13, 2023	BUY	$0.09 - $0.2 $1 - $3	16 Added 0.44%	3,642 $0
Q3 2022 Nov 14, 2022	BUY	$0.15 - $3.02 $40 - $806	267 Added 7.95%	3,626 $1,000
Q2 2022 Aug 12, 2022	SELL	$1.76 - $3.33 $18,735 - $35,447	-10,645 Reduced 76.01%	3,359 $6,000
Q1 2022 May 16, 2022	SELL	$1.81 - $3.97 $30,789 - $67,533	-17,011 Reduced 54.85%	14,004 $42,000
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $23,438 - $52,640	6,404 Added 26.02%	31,015 $115,000
Q3 2021 Nov 15, 2021	BUY	$5.93 - $17.83 $124,150 - $373,288	20,936 Added 569.69%	24,611 $147,000
Q2 2021 Aug 16, 2021	BUY	$13.54 - $22.74 $9,112 - $15,304	673 Added 22.42%	3,675 $64,000
Q1 2021 May 13, 2021	SELL	$12.91 - $23.83 $275,202 - $507,984	-21,317 Reduced 87.66%	3,002 $57,000
Q4 2020 Feb 09, 2021	BUY	$7.97 - $21.66 $193,822 - $526,749	24,319 New	24,319 $426,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.